CSIMarket



Best Performing Stocks In Major Pharmaceutical Preparations Industry During This Current Quarter Q2 Of 2024



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares declined by -0.43% on average, in Major Pharmaceutical Preparations Industry during this current quarter q2 of 2024.

Here are the best performing stocks in Major Pharmaceutical Preparations Industry.




TNXP

$1.3

$0.9790 304.98%
This Quarter Q2 of 2024


TNXP

$1.3

$0.9790 304.98%



Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp shares increased 304.98% during this current quarter q2 of 2024.


Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 105.143 mill. $ 10.250 mill. $ -102.616 mill. 81 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 105.143 mill.


$ 10.250 mill.


$ -102.616 mill.

Employees Shares Outstanding P/E

-


81 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GRI

$2.66

$1.8873 244.25%
This Quarter Q2 of 2024


GRI

$2.66

$1.8873 244.25%



Gri Bio Inc

Gri Bio Inc shares increased 244.25% during this current quarter q2 of 2024.


Gri Bio Inc*s business model focuses on providing innovative biotechnology solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10.979 mill. $ - mill. $ -12.528 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 10.979 mill.


$ - mill.


$ -12.528 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELYM

$8.29

$5.5900 207.04%
This Quarter Q2 of 2024


ELYM

$8.29

$5.5900 207.04%



Eliem Therapeutics Inc

Eliem Therapeutics Inc shares increased 207.04% during this current quarter q2 of 2024.


Eliem Therapeutics Inc*s business model revolves around developing and commercializing innovative therapeutic solutions for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 224.419 mill. $ - mill. $ -39.240 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 224.419 mill.


$ - mill.


$ -39.240 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AVTX

$13.04

$8.6700 198.40%
This Quarter Q2 of 2024


AVTX

$13.04

$8.6700 198.40%



Avalo Therapeutics Inc

Avalo Therapeutics Inc stock increased 198.40% during this current quarter q2 of 2024.


Avalo Therapeutics Inc is a biotechnology company that focuses on developing novel cancer therapies. Their business model revolves around discovering and advancing targeted therapeutics using their proprietary platform technology. They aim to bring innovative treatments to patients by employing a combination of scientific expertise, strategic collaborations, and clinical development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.217 mill. $ - mill. $ -142.879 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 11.217 mill.


$ - mill.


$ -142.879 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RSPI

$0.0029

$0.0019 190.00%
This Quarter Q2 of 2024


RSPI

$0.0029

$0.0019 190.00%



Respirerx Pharmaceuticals Inc

Respirerx Pharmaceuticals Inc stock went up 190.00% during this current quarter q2 of 2024.


Respirerx Pharmaceuticals Inc is a pharmaceutical company that focuses on developing and commercializing therapeutics for the treatment of respiratory diseases. Their business model centers around research, development, and marketing of innovative respiratory drugs to improve patient outcomes and address unmet medical needs in this field.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.488 mill. $ - mill. $ -3.403 mill. 168 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.488 mill.


$ - mill.


$ -3.403 mill.

Employees Shares Outstanding P/E

-


168 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ETST

$0.21

$0.1350 180.00%
This Quarter Q2 of 2024


ETST

$0.21

$0.1350 180.00%



Earth Science Tech Inc

Earth Science Tech Inc stock went up 180.00% during this current quarter q2 of 2024.


Earth Science Tech Inc is a biotechnology company focused on developing and marketing innovative hemp cannabinoid-based products. Their business model revolves around research, development, manufacturing, and distribution of high-quality CBD and nutraceuticals for various industries, including the pharmaceutical and nutrition sectors.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 5.570 mill. $ 0.542 mill. - mill. - Y/Y 133,208.25 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 5.570 mill.


$ 0.542 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y 133,208.25 %


MRQ Y/Y - %



EBS

$6.52

$4.0700 166.12%
This Quarter Q2 of 2024


EBS

$6.52

$4.0700 166.12%



Emergent Biosolutions Inc

Emergent Biosolutions Inc shares improved 166.12% during this current quarter q2 of 2024.


Emergent Biosolutions Inc*s business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 340.344 mill. $ 1,184.600 mill. $ -568.500 mill. 52 mill. - Y/Y 81.95 %
Market Cap. Revenues TTM Net Income TTM

$ 340.344 mill.


$ 1,184.600 mill.


$ -568.500 mill.

Employees Shares Outstanding P/E

2,100


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 81.95 %


MRQ Y/Y - %



INSM

$67.99

$42.2700 164.35%
This Quarter Q2 of 2024


INSM

$67.99

$42.2700 164.35%



Insmed Inc

Insmed Inc shares improved 164.35% during this current quarter q2 of 2024.


Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company*s business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc*s efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10,093.523 mill. $ 319.709 mill. $ -746.894 mill. 148 mill. - Y/Y 22.27 %
Market Cap. Revenues TTM Net Income TTM

$ 10,093.523 mill.


$ 319.709 mill.


$ -746.894 mill.

Employees Shares Outstanding P/E

400


148 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.27 %


MRQ Y/Y - %



KTRA

$0.2471

$0.1530 162.59%
This Quarter Q2 of 2024


KTRA

$0.2471

$0.1530 162.59%



Kintara Therapeutics Inc

Kintara Therapeutics Inc shares went up 162.59% during this current quarter q2 of 2024.


Kintara Therapeutics Inc*s business model revolves around the development and commercialization of innovative therapies for the treatment of various types of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.425 mill. $ - mill. $ -13.023 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.425 mill.


$ - mill.


$ -13.023 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



XTLB

$2.235

$1.3550 153.98%
This Quarter Q2 of 2024


XTLB

$2.235

$1.3550 153.98%



Xtl Biopharmaceuticals Ltd

Xtl Biopharmaceuticals Ltd stock improved 153.98% during this current quarter q2 of 2024.


Xtl Biopharmaceuticals Ltd*s business model revolves around developing and commercializing innovative biopharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,217.865 mill. $ - mill. $ 0.000 mill. 545 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,217.865 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


545 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MAIA

$3.15

$1.7600 126.62%
This Quarter Q2 of 2024


MAIA

$3.15

$1.7600 126.62%



Maia Biotechnology Inc

Maia Biotechnology Inc shares went up 126.62% during this current quarter q2 of 2024.


Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 43.079 mill. $ - mill. $ -5.307 mill. 14 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 43.079 mill.


$ - mill.


$ -5.307 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



STOK

$14.23

$7.8400 122.69%
This Quarter Q2 of 2024


STOK

$14.23

$7.8400 122.69%



Stoke Therapeutics Inc

Stoke Therapeutics Inc stock increased 122.69% during this current quarter q2 of 2024.


Stoke Therapeutics Inc operates on a therapeutic platform that utilizes antisense oligonucleotides to target genetic diseases. The company focuses on developing treatments for severe genetic epilepsies, genetic conditions related to a haploinsufficiency gene, and other genetic disorders that lack effective therapies. Their business model centers around identifying and developing novel therapies that modulate gene expression to address the underlying cause of these diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 629.905 mill. $ 9.248 mill. $ -103.396 mill. 44 mill. - Y/Y 13.87 %
Market Cap. Revenues TTM Net Income TTM

$ 629.905 mill.


$ 9.248 mill.


$ -103.396 mill.

Employees Shares Outstanding P/E

-


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 13.87 %


MRQ Y/Y - %



RZLT

$3.95

$2.1700 121.91%
This Quarter Q2 of 2024


RZLT

$3.95

$2.1700 121.91%



Rezolute Inc

Rezolute Inc shares went up 121.91% during this current quarter q2 of 2024.


Rezolute Inc*s business model involves developing and commercializing innovative therapies, focusing on rare and severe chronic metabolic and orphan diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 200.703 mill. $ - mill. $ -58.211 mill. 51 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 200.703 mill.


$ - mill.


$ -58.211 mill.

Employees Shares Outstanding P/E

-


51 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HROW

$21

$10.5100 100.19%
This Quarter Q2 of 2024


HROW

$21

$10.5100 100.19%



Harrow Inc

Harrow Inc stock went up 100.19% during this current quarter q2 of 2024.


Harrow Health Inc*s business model focuses on developing and commercializing innovative healthcare products and solutions, with a strong emphasis on specialty pharmaceuticals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 744.862 mill. $ 137.484 mill. $ -31.333 mill. 35 mill. - Y/Y 30.38 %
Market Cap. Revenues TTM Net Income TTM

$ 744.862 mill.


$ 137.484 mill.


$ -31.333 mill.

Employees Shares Outstanding P/E

257


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 30.38 %


MRQ Y/Y - %



IBIO

$2.1

$1.0500 100.00%
This Quarter Q2 of 2024


IBIO

$2.1

$1.0500 100.00%



Ibio inc

Ibio Inc shares improved 100.00% during this current quarter q2 of 2024.


Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.797 mill. $ - mill. $ -22.245 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 7.797 mill.


$ - mill.


$ -22.245 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CNTX

$2.16

$1.0700 98.17%
This Quarter Q2 of 2024


CNTX

$2.16

$1.0700 98.17%



Context Therapeutics Inc

Context Therapeutics Inc shares went up 98.17% during this current quarter q2 of 2024.


Context Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative cancer therapies. Their business model centers around the discovery and development of novel drugs that specifically target and inhibit the growth of hormone-driven cancers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 34.487 mill. $ - mill. $ -21.324 mill. 16 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 34.487 mill.


$ - mill.


$ -21.324 mill.

Employees Shares Outstanding P/E

-


16 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LPCN

$8.98

$4.3800 95.22%
This Quarter Q2 of 2024


LPCN

$8.98

$4.3800 95.22%



Lipocine Inc

Lipocine Inc stock went up 95.22% during this current quarter q2 of 2024.


Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 47.009 mill. $ -2.851 mill. $ -16.352 mill. 5 mill. - Y/Y 164.58 %
Market Cap. Revenues TTM Net Income TTM

$ 47.009 mill.


$ -2.851 mill.


$ -16.352 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 164.58 %


MRQ Y/Y - %



AKTX

$3.71

$1.7400 88.32%
This Quarter Q2 of 2024


AKTX

$3.71

$1.7400 88.32%



Akari Therapeutics Plc

Akari Therapeutics Plc shares went up 88.32% during this current quarter q2 of 2024.


Akari Therapeutics Plc is a biopharmaceutical company that develops and commercializes treatments for autoimmune and inflammatory diseases. Their business model revolves around conducting research, clinical trials, and obtaining regulatory approvals for their product candidates. They aim to provide innovative therapies to patients and generate revenue through the sale and licensing of their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,158.162 mill. $ - mill. $ -17.748 mill. 312 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,158.162 mill.


$ - mill.


$ -17.748 mill.

Employees Shares Outstanding P/E

15


312 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELVN

$21.44

$9.4700 79.11%
This Quarter Q2 of 2024


ELVN

$21.44

$9.4700 79.11%



Enliven Therapeutics Inc

Enliven Therapeutics Inc stock improved 79.11% during this current quarter q2 of 2024.


Enliven Therapeutics Inc*s business model focuses on developing and providing effective therapeutic solutions that enhance patient wellness and quality of life.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 879.702 mill. $ - mill. $ -20.029 mill. 41 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 879.702 mill.


$ - mill.


$ -20.029 mill.

Employees Shares Outstanding P/E

-


41 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



UPC

$2.63

$1.1500 77.70%
This Quarter Q2 of 2024


UPC

$2.63

$1.1500 77.70%



Universe Pharmaceuticals Inc

Universe Pharmaceuticals Inc shares increased 77.70% during this current quarter q2 of 2024.


Universe Pharmaceuticals Inc is a pharmaceutical company that follows a business model focused on research, development, and manufacturing of medications. They aim to identify and address unmet medical needs by developing innovative pharmaceutical products. Through strategic partnerships and collaborations, they strive to bring their products to market and provide effective healthcare solutions to patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.534 mill. $ 32.309 mill. $ -6.163 mill. 4 mill. - Y/Y -19.52 %
Market Cap. Revenues TTM Net Income TTM

$ 9.534 mill.


$ 32.309 mill.


$ -6.163 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -19.52 %


MRQ Y/Y - %



ELDN

$2.73

$1.1900 77.27%
This Quarter Q2 of 2024


ELDN

$2.73

$1.1900 77.27%



Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc shares improved 77.27% during this current quarter q2 of 2024.


Eledon Pharmaceuticals Inc is a pharmaceutical company that operates on a research and development model, focusing on the discovery and development of innovative drugs in various therapeutic areas. They aim to bring new drugs to market by conducting extensive research, clinical trials, and partnering with other pharmaceutical companies for manufacturing and distribution.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 81.830 mill. $ - mill. $ -89.084 mill. 30 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 81.830 mill.


$ - mill.


$ -89.084 mill.

Employees Shares Outstanding P/E

-


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



COCP

$2.66

$1.1400 75.00%
This Quarter Q2 of 2024


COCP

$2.66

$1.1400 75.00%



Cocrystal Pharma Inc

Cocrystal Pharma Inc shares went up 75.00% during this current quarter q2 of 2024.


Cocrystal Pharma Inc.*s business model focuses on the development of antiviral therapeutics to address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 27.063 mill. $ - mill. $ -16.240 mill. 10 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 27.063 mill.


$ - mill.


$ -16.240 mill.

Employees Shares Outstanding P/E

11


10 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CALT

$38.73

$16.4300 73.68%
This Quarter Q2 of 2024


CALT

$38.73

$16.4300 73.68%



Calliditas Therapeutics Ab

Calliditas Therapeutics Ab stock improved 73.68% during this current quarter q2 of 2024.


Calliditas Therapeutics Ab*s business model is focused on developing and commercializing innovative pharmaceutical products to address unmet medical needs in niche markets.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,078.719 mill. $ 129.241 mill. $ -50.115 mill. 54 mill. - Y/Y 49.74 %
Market Cap. Revenues TTM Net Income TTM

$ 2,078.719 mill.


$ 129.241 mill.


$ -50.115 mill.

Employees Shares Outstanding P/E

60


54 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 49.74 %


MRQ Y/Y - %



SMMT

$7.93

$3.3100 71.65%
This Quarter Q2 of 2024


SMMT

$7.93

$3.3100 71.65%



Summit Therapeutics Inc

Summit Therapeutics Inc stock went up 71.65% during this current quarter q2 of 2024.


Summit Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of rare diseases. The company employs a research-driven business model, leveraging its proprietary technologies and expertise to identify and develop novel drugs targeting specific genetic mutations associated with these rare diseases. Summit Therapeutics Inc aims to bring its drug candidates through preclinical and clinical development stages and ultimately secure regulatory approval and commercialize them to benefit patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,565.157 mill. $ - mill. $ -116.025 mill. 702 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,565.157 mill.


$ - mill.


$ -116.025 mill.

Employees Shares Outstanding P/E

70


702 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IGC

$0.55

$0.2255 69.49%
This Quarter Q2 of 2024


IGC

$0.55

$0.2255 69.49%



Igc Pharma Inc

Igc Pharma Inc shares increased 69.49% during this current quarter q2 of 2024.


Igc Pharma Inc*s business model revolves around the development and commercialization of innovative therapeutics derived from cannabis-based compounds. The company focuses on researching treatments for indications such as epilepsy, pain, and inflammation. Igc Pharma Inc primarily operates in the pharmaceutical industry, aiming to provide safe and effective alternatives to conventional medicines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 35.049 mill. $ 1.215 mill. $ -14.145 mill. 64 mill. - Y/Y -38.55 %
Market Cap. Revenues TTM Net Income TTM

$ 35.049 mill.


$ 1.215 mill.


$ -14.145 mill.

Employees Shares Outstanding P/E

-


64 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -38.55 %


MRQ Y/Y - %



CVSI

$0.0565

$0.0229 68.15%
This Quarter Q2 of 2024


CVSI

$0.0565

$0.0229 68.15%



Cv Sciences Inc

Cv Sciences Inc shares improved 68.15% during this current quarter q2 of 2024.


Cv Sciences Inc operates through a business model focused on the production and sale of cannabidiol (CBD) based products. The company sources hemp for extraction, processes it into various CBD products, and distributes them through multiple channels, including online sales and retail partnerships. By leveraging the growing demand for CBD, Cv Sciences Inc aims to generate revenue and establish a market presence in the emerging health and wellness industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 8.735 mill. $ 15.578 mill. $ 1.658 mill. 155 mill. 3.16 Y/Y 2.45 %
Market Cap. Revenues TTM Net Income TTM

$ 8.735 mill.


$ 15.578 mill.


$ 1.658 mill.

Employees Shares Outstanding P/E

-


155 mill.


3.16

Revenue Growth Income Growth

MRQ Y/Y 2.45 %


MRQ Y/Y - %



AVRW

$0.0499

$0.0195 64.14%
This Quarter Q2 of 2024


AVRW

$0.0499

$0.0195 64.14%



Avenir Wellness Solutions Inc

Avenir Wellness Solutions Inc shares increased 64.14% during this current quarter q2 of 2024.


Avenir Wellness Solutions Inc is a health and wellness company that operates through a subscription-based model. They offer personalized wellness programs, incorporating nutrition, fitness, and mental health, to their members. With a focus on providing comprehensive and tailored services, Avenir Wellness Solutions Inc aims to promote overall well-being and help individuals achieve their health goals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.231 mill. $ 4.575 mill. $ -4.530 mill. 65 mill. - Y/Y -89.88 %
Market Cap. Revenues TTM Net Income TTM

$ 3.231 mill.


$ 4.575 mill.


$ -4.530 mill.

Employees Shares Outstanding P/E

-


65 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -89.88 %


MRQ Y/Y - %



NRIX

$21.3

$8.2200 62.84%
This Quarter Q2 of 2024


NRIX

$21.3

$8.2200 62.84%



Nurix Therapeutics Inc

Nurix Therapeutics Inc shares increased 62.84% during this current quarter q2 of 2024.


Nurix Therapeutics Inc*s business model involves developing targeted protein degradation therapies to treat diseases by modulating the body*s cellular protein levels.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,169.443 mill. $ 80.887 mill. $ -144.733 mill. 55 mill. - Y/Y 30.74 %
Market Cap. Revenues TTM Net Income TTM

$ 1,169.443 mill.


$ 80.887 mill.


$ -144.733 mill.

Employees Shares Outstanding P/E

100


55 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 30.74 %


MRQ Y/Y - %



VNDA

$6.12

$2.3100 60.63%
This Quarter Q2 of 2024


VNDA

$6.12

$2.3100 60.63%



Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc shares increased 60.63% during this current quarter q2 of 2024.


Vanda Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of innovative therapies for central nervous system disorders. Their business model revolves around conducting research and development activities to identify potential drug candidates, securing intellectual property rights, and seeking regulatory approvals for the commercialization of their products. Through partnerships and collaborations, they aim to bring their novel therapies to market and improve the lives of patients suffering from neurological disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 353.497 mill. $ 177.604 mill. $ -4.889 mill. 58 mill. - Y/Y -24.06 %
Market Cap. Revenues TTM Net Income TTM

$ 353.497 mill.


$ 177.604 mill.


$ -4.889 mill.

Employees Shares Outstanding P/E

500


58 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -24.06 %


MRQ Y/Y - %



TLSA

$0.8

$0.3003 60.10%
This Quarter Q2 of 2024


TLSA

$0.8

$0.3003 60.10%



Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd shares increased 60.10% during this current quarter q2 of 2024.


Tiziana Life Sciences Ltd*s business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 83.252 mill. $ - mill. $ -17.691 mill. 104 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 83.252 mill.


$ - mill.


$ -17.691 mill.

Employees Shares Outstanding P/E

-


104 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNA

$39

$14.5800 59.71%
This Quarter Q2 of 2024


RNA

$39

$14.5800 59.71%



Avidity Biosciences Inc

Avidity Biosciences Inc stock went up 59.71% during this current quarter q2 of 2024.


Avidity Biosciences Inc*s business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,401.268 mill. $ 10.870 mill. $ -228.681 mill. 87 mill. - Y/Y 58.67 %
Market Cap. Revenues TTM Net Income TTM

$ 3,401.268 mill.


$ 10.870 mill.


$ -228.681 mill.

Employees Shares Outstanding P/E

-


87 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 58.67 %


MRQ Y/Y - %



VRCA

$7.45

$2.6500 55.21%
This Quarter Q2 of 2024


VRCA

$7.45

$2.6500 55.21%



Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc stock improved 55.21% during this current quarter q2 of 2024.


Verrica Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing medical solutions for dermatological conditions. Their business model revolves around identifying unmet needs in the dermatology market, conducting rigorous clinical research to develop novel therapies, and efficiently bringing these treatments to market through strategic partnerships and collaborations. Verrica Pharmaceuticals aims to enhance patient outcomes by addressing specific dermatological conditions with innovative solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 343.251 mill. $ 3.204 mill. $ -48.313 mill. 46 mill. - Y/Y -64.94 %
Market Cap. Revenues TTM Net Income TTM

$ 343.251 mill.


$ 3.204 mill.


$ -48.313 mill.

Employees Shares Outstanding P/E

-


46 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -64.94 %


MRQ Y/Y - %



DERM

$5.18

$1.7800 52.35%
This Quarter Q2 of 2024


DERM

$5.18

$1.7800 52.35%



Journey Medical Corporation

Journey Medical Corporation stock increased 52.35% during this current quarter q2 of 2024.


Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 102.344 mill. $ 79.998 mill. $ -4.159 mill. 20 mill. - Y/Y 6.69 %
Market Cap. Revenues TTM Net Income TTM

$ 102.344 mill.


$ 79.998 mill.


$ -4.159 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 6.69 %


MRQ Y/Y - %



NNVC

$1.82

$0.6200 51.67%
This Quarter Q2 of 2024


NNVC

$1.82

$0.6200 51.67%



Nanoviricides inc

Nanoviricides Inc stock increased 51.67% during this current quarter q2 of 2024.


Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.439 mill. $ - mill. $ -9.508 mill. 12 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 21.439 mill.


$ - mill.


$ -9.508 mill.

Employees Shares Outstanding P/E

-


12 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AGIO

$45.22

$15.2800 51.04%
This Quarter Q2 of 2024


AGIO

$45.22

$15.2800 51.04%



Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc shares went up 51.04% during this current quarter q2 of 2024.


Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,549.661 mill. $ 29.403 mill. $ -352.619 mill. 56 mill. - Y/Y 46.00 %
Market Cap. Revenues TTM Net Income TTM

$ 2,549.661 mill.


$ 29.403 mill.


$ -352.619 mill.

Employees Shares Outstanding P/E

-


56 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 46.00 %


MRQ Y/Y - %



SNOA

$0.2017

$0.0644 46.90%
This Quarter Q2 of 2024


SNOA

$0.2017

$0.0644 46.90%



Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc stock went up 46.90% during this current quarter q2 of 2024.


Sonoma Pharmaceuticals Inc operates as a healthcare company that specializes in developing and manufacturing innovative products for various dermatological conditions. They focus on commercializing and distributing advanced solutions for wound care, dermatoses, and other skin disorders, aiming to provide effective treatment options to patients and healthcare professionals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 12.310 mill. $ -5.076 mill. - mill. 0.16 Y/Y 6.59 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 12.310 mill.


$ -5.076 mill.

Employees Shares Outstanding P/E

-


- mill.


0.16

Revenue Growth Income Growth

MRQ Y/Y 6.59 %


MRQ Y/Y - %



NXEN

$0.0238

$0.0075 46.01%
This Quarter Q2 of 2024


NXEN

$0.0238

$0.0075 46.01%



Nexien Biopharma Inc

Nexien Biopharma Inc shares increased 46.01% during this current quarter q2 of 2024.


Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.580 mill. $ - mill. $ -0.246 mill. 66 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.580 mill.


$ - mill.


$ -0.246 mill.

Employees Shares Outstanding P/E

-


66 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PAHC

$17.64

$5.3000 42.95%
This Quarter Q2 of 2024


PAHC

$17.64

$5.3000 42.95%



Phibro Animal Health Corporation

Phibro Animal Health Corporation stock went up 42.95% during this current quarter q2 of 2024.


Phibro Animal Health Corporation is a leading global provider of animal health and nutrition products, catering to both livestock and companion animals. Their business model centers around producing and marketing a wide range of pharmaceuticals, vaccines, nutritional supplements, and other animal health products. They aim to serve the diverse needs of farmers, veterinarians, and pet owners, while focusing on innovation, quality, and customer satisfaction.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 714.773 mill. $ 997.339 mill. $ 13.162 mill. 41 mill. 54.47 Y/Y 6.89 %
Market Cap. Revenues TTM Net Income TTM

$ 714.773 mill.


$ 997.339 mill.


$ 13.162 mill.

Employees Shares Outstanding P/E

1,400


41 mill.


54.47

Revenue Growth Income Growth

MRQ Y/Y 6.89 %


MRQ Y/Y -16.30 %



RNAZ

$0.9689

$0.2779 40.22%
This Quarter Q2 of 2024


RNAZ

$0.9689

$0.2779 40.22%



Transcode Therapeutics Inc

Transcode Therapeutics Inc shares increased 40.22% during this current quarter q2 of 2024.


Transcode Therapeutics Inc*s business model revolves around developing innovative RNA-based therapies to treat a wide range of diseases. By leveraging their expertise in mRNA biology and proprietary drug delivery technology, they aim to create transformative treatments with optimized safety and efficacy profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.982 mill. $ - mill. $ -17.056 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.982 mill.


$ - mill.


$ -17.056 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



JAGX

$3.92

$1.1200 40.00%
This Quarter Q2 of 2024


JAGX

$3.92

$1.1200 40.00%



Jaguar Health Inc

Jaguar Health Inc stock improved 40.00% during this current quarter q2 of 2024.


Jaguar Health Inc*s business model revolves around developing and commercializing natural, plant-based products for human and animal health. They aim to provide innovative solutions utilizing their scientific expertise in the development of novel medicines and consumer healthcare products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 622.662 mill. $ 10.140 mill. $ -38.872 mill. 159 mill. - Y/Y 19.22 %
Market Cap. Revenues TTM Net Income TTM

$ 622.662 mill.


$ 10.140 mill.


$ -38.872 mill.

Employees Shares Outstanding P/E

-


159 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 19.22 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com